<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00783250</url>
  </required_header>
  <id_info>
    <org_study_id>350</org_study_id>
    <nct_id>NCT00783250</nct_id>
  </id_info>
  <brief_title>Bronchodilators and Respiratory Mechanics in Chronic Obstructive Pulmonary Disease (COPD) Patients</brief_title>
  <official_title>Effect of Bronchodilators on Respiratory Mechanics in COPD Patients With Poor Reversibility</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IRCCS Azienda Ospedaliero-Universitaria di Bologna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IRCCS Azienda Ospedaliero-Universitaria di Bologna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to assess the effects on respiratory mechanics of one &quot;classical&quot;&#xD;
      short-term bronchodilator (i.e., salbutamol) versus placebo, and to verify the hypothesis&#xD;
      that the addition of another bronchodilator (i.e., anticholinergic) may induce a further&#xD;
      improvement on the work of breathing of stable COPD patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Studies with long-acting b2-agonists in COPD patients who poorly respond to routine airways&#xD;
      obstruction reversibility tests with forced expiratory manoeuvres, such as forced expiratory&#xD;
      volume in one second (FEV1), are scarce. Such studies, however, seem to show favourable&#xD;
      effects on clinical parameters.&#xD;
&#xD;
      This may explain the subjective improvements and changes in quality of life with long-acting&#xD;
      b2-agonists in patients with COPD. The lack of effect on forced expiration tests may be due&#xD;
      to early airway collapse and subsequent airflow decline causing underestimation of the&#xD;
      existing bronchodilatory effects located more peripherally in the respiratory tract, where&#xD;
      the major site of resistance is located in obstructive lung disease.&#xD;
&#xD;
      We therefore design a study aimed to assess the short term effects of one short-acting&#xD;
      beta2-agonist vs placebo, and the effects of an additional and sequential administration of a&#xD;
      different bronchodilator, like tiotropium bromide (anticholinergic agent) on the work of&#xD;
      breathing, and its components (i.e., lung resistances and compliance) of COPD patients with&#xD;
      poor reversibility assessed using the classical Pulmonary Function Tests.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Problems with data collection&#xD;
  </why_stopped>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">August 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recordings of respiratory mechanics</measure>
    <time_frame>90 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dyspnea score</measure>
    <time_frame>90 minutes</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Salbutamol+Tiotropium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Salbutamol will be given at the dose of 400 micrograms and Tiotropium at the dose of 18 micrograms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo + Tiotropium</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo using MDI + administration of Tiotropium after 20 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salbutamol + Tiotropium</intervention_name>
    <description>Salbutamol 400 micrograms + Tiotropium 18 micrograms</description>
    <arm_group_label>Salbutamol+Tiotropium</arm_group_label>
    <other_name>Ventolin</other_name>
    <other_name>Spiriva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo + Tiotropium</intervention_name>
    <description>Placebo via MDI + Tiotropium 18 micrograms</description>
    <arm_group_label>placebo + Tiotropium</arm_group_label>
    <other_name>Spiriva</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  COPD patient with a Tiffenau ratio &lt;55% and &gt;25% predicted&#xD;
&#xD;
          -  Poor reversibility to an acute bronchodilator test (i.e. FEV1 changes&lt;10% from&#xD;
             baseline)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Lack of informed consent&#xD;
&#xD;
          -  Cancer&#xD;
&#xD;
          -  Concomitant lung and airways diseases&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Respiratory Unit Fondazione S.Maugeri</name>
      <address>
        <city>Pavia</city>
        <state>PV</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>October 30, 2008</study_first_submitted>
  <study_first_submitted_qc>October 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2008</study_first_posted>
  <last_update_submitted>July 16, 2012</last_update_submitted>
  <last_update_submitted_qc>July 16, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>IRCCS Azienda Ospedaliero-Universitaria di Bologna</investigator_affiliation>
    <investigator_full_name>dr. Stefano Nava</investigator_full_name>
    <investigator_title>Chief ICU</investigator_title>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>Respiratory Mechanics</keyword>
  <keyword>Bronchodilators</keyword>
  <keyword>COPD patients with poor reversibility</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Albuterol</mesh_term>
    <mesh_term>Tiotropium Bromide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

